| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MCRB | Common Stock | Options Exercise | $0 | +13,745 | $0.000000 | 13,745 | 27 Oct 2023 | Direct | F1 | |
| transaction | MCRB | Common Stock | Sale | $5,713 | -4,232 | -31% | $1.35 | 9,513 | 30 Oct 2023 | Direct | F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MCRB | Restricted Stock Units | Award | $0 | +27,489 | $0.000000 | 27,489 | 27 Apr 2023 | Common Stock | 27,489 | Direct | F1, F4 | ||
| transaction | MCRB | Restricted Stock Units | Options Exercise | $0 | -13,745 | -50% | $0.000000 | 13,744 | 27 Oct 2023 | Common Stock | 13,745 | Direct | F1, F4 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. |
| F2 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on July 2, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs. |
| F3 | The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.3406 to $1.4115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. |
Executive Vice President and Chief Medical Officer